Regeneron Pharmaceuticals Inc (REGN) Q1 2021 Earnings Call Transcript
REGN earnings call for the period ending March 31, 2021.
Regeneron Pharmaceuticals(REGN)
Nasdaq Global Select
REGN
$496.75
-$1.93
-0.4%
Price as of May 7, 2021, 4:00 p.m. ET
View Interactive REGN Charts
The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.
Interactive Chart
News & Analysis: Regeneron Pharmaceuticals
The Fool has written over 500 articles on Regeneron Pharmaceuticals.
Why Regeneron's Q1 Results Looked Great Despite Its Revenue Miss
The big biotech delivered impressive revenue and earnings growth.
Buy Alert: Regeneron Stock Is Headed Higher
A new delivery method for its COVID-19 treatment may offer a boost.
Will Regeneron's COVID Cocktail Win Be Short-Lived?
The biotech's antibody therapy continues to show promise. But there's considerable uncertainty about its long-term prospects.
3 Stocks Cathie Wood Is Selling That Long-Term Investors Should Be Buying
Their growth prospects are too good to ignore.
Could Regeneron's Antibody Therapy Be as Important as Vaccines in Fighting COVID?
There are a couple of obstacles that could get in the way.
2 Great Stocks You Can Buy on Sale
There aren't many deals out there right now, but these are two of the better ones you can snag.
Beyond COVID, Regeneron Is Betting Big on Oncology
Future growth will depend on its new checkpoint inhibitor wrangling market share away from Merck's Keytruda.
2 Best Pharma Stocks to Buy Right Now
These under-appreciated pharma stocks have the potential to become long-term winners.
Should You Follow Cathie Wood Into This Coronavirus Stock?
This latest pick has been sluggish so far -- but the long-term opportunity may be huge.
